Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Centessa Pharmaceuticals (Nasdaq: CNTA) announced its participation in upcoming investor conferences. Members of its management team will present at the Jefferies Global Healthcare Conference on June 6, 2024, in New York, NY, and at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami, FL. Participants can access live webcasts and archived recordings of these events through the company's investor relations website.
- Centessa Pharmaceuticals' participation in prominent investor conferences may enhance visibility and attract potential investors.
- Live webcasts and archived recordings of the presentations will be accessible, providing transparency and information to current and prospective investors.
- The press release lacks specific updates on financial performance or clinical trial progress, which may be concerning for investors seeking more concrete data.
- No immediate financial or clinical milestones were announced, potentially limiting the immediate impact on the stock price.
BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
Event: Jefferies Global Healthcare Conference
Date: June 6, 2024
Location: NY, NY
Fireside Chat: 1:00 PM ET
Event: Goldman Sachs 45th Annual Global Healthcare Conference
Date: June 11, 2024
Location: Miami, FL
Fireside Chat: 11:20 AM ET
Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on our LockBody® technology platform. We operate with the conviction that each of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit www.centessa.com, which does not form part of this release.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com
FAQ
When will Centessa Pharmaceuticals participate in the Jefferies Global Healthcare Conference?
What is the date and location of the Goldman Sachs 45th Annual Global Healthcare Conference?
How can I access the webcasts of Centessa Pharmaceuticals' presentations at the investor conferences?
What is the stock symbol for Centessa Pharmaceuticals?
